A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma
Open Access
- 1 December 2018
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 367 (3) , 405-413
Abstract
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and activation. Activation of PI3Kδ has been linked to airway inflammation and asthma pathogenesis. This randomised, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability and pharmacokinetics of a PI3Kδ inhibitor, nemiralisib (GSK2269557), in patients with persistent, uncontrolled asthma. Patients (n=50) received once-daily inhaled nemiralisib (1000 µg) or placebo for 28 days, with a crossover to the alternative treatment following a 4-week washout period. Spirometry demonstrated no discernible difference in trough forced expiratory volume in 1 second (FEV1) from baseline (adjusted posterior median 7 mL; 95% credible interval -83 mL, 102 mL) between nemiralisib and placebo treatment at Day 28 (primary endpoint). These results were supported by most secondary endpoints, including weighted mean FEV1 (0-4 h) and change in trough forced vital capacity at Day 28. Nemiralisib was generally well-tolerated, with few side effects except for post-inhalation cough (nemiralisib: 35%; placebo: 9%). At Day 28, sputum interleukin (IL)-5, IL-13, IL-6 and IL-8 levels were reduced by a median of 17%, 7%, 15% and 8%, respectively, when comparing nemiralisib with placebo (n=15 [IL-5, IL-8] or 16 [IL-6, IL-13]; posterior probability of a true ratio >0%: 78%, 64%, 76% and 63%, respectively). These results suggest that nemiralisib inhibited PI3Kδ locally; however, this did not translate into meaningful clinical improvement. Further studies will investigate the potential efficacy of nemiralisib in patients with asthma with other specific more severe phenotypes, including those who are colonised with bacteria and frequently exacerbate.Keywords
This publication has 34 references indexed in Scilit:
- Role played by Th2 type cytokines in IgE mediated allergy and asthmaLung India, 2010
- Natural killer T cells and the regulation of asthmaMucosal Immunology, 2009
- Phosphoinositide 3‐kinase δ inhibitor as a novel therapeutic agent in asthmaRespirology, 2008
- Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy ModelJournal of Allergy and Clinical Immunology, 2007
- Role of the phosphoinositide 3‐kinase p110δ in generation of type 2 cytokine responses and allergic airway inflammationEuropean Journal of Immunology, 2007
- Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3KTrends in Immunology, 2007
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and ActivationJournal of Experimental Medicine, 2002
- Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant MiceScience, 2002
- Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic AsthmaNew England Journal of Medicine, 1992